These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes. Akesson L, Ahrén B, Edgren G, Degerman E. Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088 [Abstract] [Full Text] [Related]
12. Identification of key residues that cause differential gallbladder response to PACAP and VIP in the guinea pig. Wei M, Fujiki K, Ando E, Zhang S, Ozaki T, Ishiguro H, Kondo T, Nokihara K, Wray V, Naruse S. Am J Physiol Gastrointest Liver Physiol; 2007 Jan; 292(1):G76-83. PubMed ID: 16901992 [Abstract] [Full Text] [Related]
13. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate. Solano RM, Carmena MJ, Carrero I, Cavallaro S, Roman F, Hueso C, Travali S, Lopez-Fraile N, Guijarro LG, Prieto JC. Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902 [Abstract] [Full Text] [Related]
14. Neuronal and smooth muscle receptors involved in the PACAP- and VIP-induced relaxations of the pig urinary bladder neck. Hernández M, Barahona MV, Recio P, Benedito S, Martínez AC, Rivera L, García-Sacristán A, Prieto D, Orensanz LM. Br J Pharmacol; 2006 Sep; 149(1):100-9. PubMed ID: 16847435 [Abstract] [Full Text] [Related]
15. Inhibitory pathways in the circular muscle of rat jejunum. Vanneste G, Robberecht P, Lefebvre RA. Br J Pharmacol; 2004 Sep; 143(1):107-18. PubMed ID: 15302684 [Abstract] [Full Text] [Related]
16. Relaxant effects of pituitary adenylate cyclase activating polypeptide (PACAP) on epithelium-intact and -denuded guinea-pig trachea: a comparison with vasoactive intestinal peptide (VIP). Conroy DM, St-Pierre S, Sirois P. Neuropeptides; 1995 Sep; 29(3):121-7. PubMed ID: 8538872 [Abstract] [Full Text] [Related]
17. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland. Mazzocchi G, Malendowicz LK, Neri G, Andreis PG, Ziolkowska A, Gottardo L, Nowak KW, Nussdorfer GG. Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629 [Abstract] [Full Text] [Related]
18. PACAP and VIP inhibit pyloric muscle through VIP/PACAP-preferring receptors. Parkman HP, Pagano AP, Ryan JP. Regul Pept; 1997 Aug 29; 71(3):185-90. PubMed ID: 9350977 [Abstract] [Full Text] [Related]
19. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals. Alexandre D, Anouar Y, Jegou S, Fournier A, Vaudry H. Endocrinology; 1999 Mar 29; 140(3):1285-93. PubMed ID: 10067855 [Abstract] [Full Text] [Related]
20. Expression and function of vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and their receptors in the human adrenal gland. Mazzocchi G, Malendowicz LK, Rebuffat P, Gottardo L, Nussdorfer GG. J Clin Endocrinol Metab; 2002 Jun 29; 87(6):2575-80. PubMed ID: 12050216 [Abstract] [Full Text] [Related] Page: [Next] [New Search]